trending Market Intelligence /marketintelligence/en/news-insights/trending/sWCcSrMgL8UmeCJXuuGp-w2 content esgSubNav
In This List

Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio

Pfizer Inc. completed the acquisition of Switzerland-based Therachon AG, which would help the company bolster its rare disease product portfolio.

The New York-based pharmaceutical giant made an up-front payment of $340 million and will pay up to an additional $470 million if Therachon's drug candidate TA-46 meets certain development and commercialization milestones.

Therachon is developing TA-46 to treat children and adolescents with achondroplasia, a genetic condition and the most common form of short-limbed dwarfism. Currently, there is no approved treatment for this condition, which can result in serious cardiovascular, neurological and metabolic complications.

TA-46, which has completed a phase 1 trial, has received the orphan drug designation in the EU and the U.S.

Pfizer said in its July 1 press release that it believes it can effectively advance the development of TA-46, which has the potential to be a first-in-class therapy for treating achondroplasia.

Pfizer added that the transaction is not expected to impact the company's 2019 adjusted financial guidance.